• 1
    Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 82733.
  • 2
    Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 5229.
  • 3
    Thompson M, Read J, Liang M. Feasibility of willingness to pay measurements in chronic arthritis. Med Decis Making 1984; 4: 195212.
  • 4
    Lubeck D, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health services utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29: 48893.
  • 5
    Jacobs J, Keyserling J, Britton M, Morgan G, Wilkenfeld J, Hutchings C. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988; 41: 21533.
  • 6
    Allaire S, Prashker M, Meenan R. The cost of rheumatoid arthritis. Pharmacoeconomics 1994; 6: 51322.
  • 7
    MacLean CH, Knight KK, Shekelle PG, Paulus HE, Brook RH. Costs attributable to arthritis implications of costs [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S317.
  • 8
    Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997; 40: 147581.
  • 9
    Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24: 71925.
  • 10
    Clarke A, Zowall H, Levinton C, Assimakopoulos H, Sibley J, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a twelve year study. J Rheumatol 1997; 24: 105160.
  • 11
    Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23 Suppl: 4751.
  • 12
    Yelin E, Henke C, Kramer J, Nevitt M, Shearn M, Epstein W. A comparison of the treatment of rheumatoid arthritis in HMOs and fee-for-service practices. N Engl J Med 1985; 312: 9627.
  • 13
    Yelin E, Criswell L, Feigenbaum P. Health care utilization and outcomes over an eleven-year period among persons with rheumatoid arthritis in fee-for-service and HMO settings. JAMA 1996; 276: 104853.
  • 14
    Gabriel S, Tugwell P, O'Brien B, Yelin E, Drummond M, Ruff B, et al. Report of the OMERACT Task Force on Economic Evaluation. Rochester (MN): Mayo Clinic; 1998.
  • 15
    Drummond M. Economic analysis alongside clinical trials: problems and potential. J Rheumatol 1995; 22: 14037.
  • 16
    Health Care Consultants of America, Inc. 1996 physicians fee and coding guide. Atlanta: Health Care Consultants of America, Inc.; 1996.
  • 17
    Medical Economics, Inc. The 1996 red book. Montvale (NJ): Medical Economics, Inc.; 1996.
  • 18
    SAS Institute, Inc. SAS/STAT software: changes and enhancements through release 6.12. Cary (NC): SAS Institute, Inc.; 1997.
  • 19
    Singh G, Terry R, Ramey D, Wolfe F, Fries J. Long-term medical costs and outcomes are significantly associated with early changes in disability in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S318.